Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer
Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.
Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer
December 1st 2017Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.
Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC
The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.
Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer
November 30th 2017Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.